Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways

Fig. 5

COMP activates MEK/ERK and PI3K/AKT pathway in HCC cells. a The levels of the indicated proteins in Hep-3B and SMMC-7721 after treatment with various concentrations of rCOMP (as indicated) as measured by Western blot. Total ERK and AKT were used as controls. b HCC cells were treated with rCOMP (2 μg /ml), rCOMP+DMSO, the MEK inhibitor U0126 (25 μM), rCOMP+U0126, PI3K inhibitor LY294002 (20 μM) and rCOMP+LY294002 for 12, 24 and 36 h, then the cell viability was evaluated using the CCK8 assay. The cell viability of every cell line with rCOMP+DMSO treatment was considered as control group. n = three independent repeats. P < 0.05 by ANOVA versus control. c HCC cells that were incubated with the indicated treatments were subjected to transwell migration and invasion assays. The number of migrated or invaded cells was counted in five different fields. n = three independent repeats. P < 0.05 by t test versus control. d The protein levels of the indicated factors after the indicated treatments were examined by Western blot. β-actin was used as a loading control. Western blot analysis was independently repeated for three times with similar results. (*P < 0.05, **P < 0.01)

Back to article page